rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
2
|
pubmed:dateCreated |
2010-4-13
|
pubmed:abstractText |
Large clinical studies assessing long-term adefovir dipivoxil salvage monotherapy in patients with lamivudine-resistant chronic hepatitis B (CHB) are lacking, particularly in patients positive for hepatitis B e antigen (HBeAg). We assessed the efficacy and resistance profile of adefovir dipivoxil monotherapy for up to 5 years in a large cohort of Korean patients with lamivudine-resistant CHB.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:issn |
2040-2058
|
pubmed:author |
|
pubmed:issnType |
Electronic
|
pubmed:volume |
15
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
235-41
|
pubmed:meshHeading |
pubmed-meshheading:20386079-Adenine,
pubmed-meshheading:20386079-Adult,
pubmed-meshheading:20386079-Aged,
pubmed-meshheading:20386079-Antiviral Agents,
pubmed-meshheading:20386079-DNA, Viral,
pubmed-meshheading:20386079-Drug Resistance, Viral,
pubmed-meshheading:20386079-Female,
pubmed-meshheading:20386079-Hepatitis B, Chronic,
pubmed-meshheading:20386079-Hepatitis B e Antigens,
pubmed-meshheading:20386079-Hepatitis B virus,
pubmed-meshheading:20386079-Humans,
pubmed-meshheading:20386079-Korea,
pubmed-meshheading:20386079-Lamivudine,
pubmed-meshheading:20386079-Male,
pubmed-meshheading:20386079-Middle Aged,
pubmed-meshheading:20386079-Phosphonic Acids,
pubmed-meshheading:20386079-Reverse Transcriptase Inhibitors,
pubmed-meshheading:20386079-Time Factors,
pubmed-meshheading:20386079-Treatment Outcome,
pubmed-meshheading:20386079-Young Adult
|
pubmed:year |
2010
|
pubmed:articleTitle |
Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B.
|
pubmed:affiliation |
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|